Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

B cells have been long studied for their role and function in the humoral immune system.
Apart from generating antibodies and an antibody-mediated memory response against …

Rationale: Atherosclerotic lesions are known for their cellular heterogeneity, yet the
molecular complexity within the cells of human plaques has not been fully assessed …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Sialic acid–binding immunoglobulin-type lectins (Siglecs) are expressed on the majority of
white blood cells of the immune system and play critical roles in immune cell signaling …

The primary purpose of ADCs is to increase the efficacy of anticancer medications by
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …

Human aging is characterized by both physical and physiological frailty that profoundly
affects the immune system. In this context aging is associated with declines in adaptive and …

Glycosylation produces an abundant, diverse, and highly regulated repertoire of cellular
glycans that are frequently attached to proteins and lipids. The past decade of research on …

Chemotherapy is one of the major therapeutic options for cancer treatment. Chemotherapy
is often associated with a low therapeutic window due to its poor specificity towards tumor …